May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Comparison of IOP-Lowering Effect of Tafluprost and Latanoprost in Ocular Hypotension Monkeys
Author Affiliations & Notes
  • N. Ishida
    Research & Development, Santen Pharmaceutical Co Ltd, Nara, Japan
  • T. Akaishi
    Research & Development, Santen Pharmaceutical Co Ltd, Nara, Japan
  • H. Kurashima
    Research & Development, Santen Pharmaceutical Co Ltd, Nara, Japan
  • M. Mieda
    Research & Development, Santen Pharmaceutical Co Ltd, Nara, Japan
  • M. Nakamura
    Research & Development, Santen Pharmaceutical Co Ltd, Nara, Japan
  • Footnotes
    Commercial Relationships  N. Ishida, Santen Pharmaceutical Co Ltd, E; T. Akaishi, Santen Pharmacetical Co Ltd, E; H. Kurashima, Santen Pharmaceutical Co Ltd, E; M. Mieda, Santen Pharmaceutical Co Ltd, E; M. Nakamura, Santen Pharmaceutical Co Ltd, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3823. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Ishida, T. Akaishi, H. Kurashima, M. Mieda, M. Nakamura; Comparison of IOP-Lowering Effect of Tafluprost and Latanoprost in Ocular Hypotension Monkeys. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3823. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Tafluprost is a new-generation prostanoid FP-receptor agonist for the treatment of glaucoma. This compound has exhibited more potent IOP-lowering effects than latanoprost in ocular normotensive and hypertensive animals. The purpose of this study is to compare the IOP-lowering efficacy of tafluprost and latanoprost in ocular hypotensive monkeys.

Methods: : This study was performed by crossover design. Nine male selected Cynomolgus monkeys (baseline IOP: 13-14 mmHg) which had been trained to accept instillation of eye drops and IOP measurement in conscious were used. Tafluprost 0.0015% (once a day), latanoprost 0.005% (once a day) or saline was topically applied to one eye for 7 days. IOP measurements were performed 0, 2, 4, 6, and 8 hour after topical application of test solutions on day 1 and day 7.

Results: : Both tafluprost and latanoprost showed IOP-reducing effect in ocular hypotension monkeys. The mean diurnal IOP on day 7 in saline group, latanoprost group and tafluprost group was 13.9 ± 0.3 mmHg, 13.0 ± 0.4 mmHg and 12.2 ± 0.3 mmHg, respectively. The maximal reductions in IOP achieved by tafluprost and latanoprost were 3.2 ± 0.3 mmHg (22% reduction) and 2.2 ± 0.3 mmHg (15% reduction), respectively. Although latanoprost did not reduce IOP at the trough time-point, tafluprost did significantly reduce trough IOP compared with saline group.

Conclusions: : Tafluprost revealed a potent IOP-reducing effect compared with latanoprost in ocular hypotension monkey eyes. This result suggesting that tafluprost may be an effective medicine for patients with low-tension glaucoma.

Keywords: intraocular pressure • eicosanoids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×